BioSpace News Archive

Results from the ongoing Phase II DESTINY-CRC01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

Detailed results from the positive registrational, randomized controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s (Daiichi Sankyo) ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS),

Peer-reviewed publication in Alzheimer’s & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study early stages of disease pathology

Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the final results from the GENUINE Phase 3 study evaluating the combination of ublituximab, the Company’s novel glycoengineered anti-CD20 monoclonal antibody, plus ibrutinib compared to ibrutinib alone in patients with previously treated high-risk chro

MDNA11, a long acting IL-2 super-agonist shows potent and durable tumor control with strong memory response in tumor models- -Up to 10-fold expansion of cancer-killing immune cells in non-human primates (NHP) without underlying safety issues or immunogenicity-

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2 clinical trial of rebastinib, the Company’s investigational orally administered, potent and selective

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML – Oral Presentations of the Phase 2 OPTIC Interim Analysis at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) Annual Meetings – – Findings Support Response-Based Dosing Regimens of ICLUSIG Can Optimize Benefit-Risk Profile in Patients with Resistant / Intol

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announced an interview with its President, Darren Lui, will air on The RedChip Money Report television program.

First-Of-Its Kind Coalition Will Convene Healthcare Leaders To Address The Extraordinary Challenges Faced By Minorities With A Rare Disease